MA32095B1 - Inhibitors of aldh-2 in the treatment of addiction - Google Patents

Inhibitors of aldh-2 in the treatment of addiction

Info

Publication number
MA32095B1
MA32095B1 MA33106A MA33106A MA32095B1 MA 32095 B1 MA32095 B1 MA 32095B1 MA 33106 A MA33106 A MA 33106A MA 33106 A MA33106 A MA 33106A MA 32095 B1 MA32095 B1 MA 32095B1
Authority
MA
Morocco
Prior art keywords
aldh
addiction
inhibitors
treatment
amphetamines
Prior art date
Application number
MA33106A
Other languages
Arabic (ar)
French (fr)
Inventor
Yaroslav Bilokin
Elfatih Elzein
Jeff Zablocki
Michael Organ
Thao Perry
Tetsuya Kobayashi
Matthew Abelman
Rao Kalla
Peidong Fan
Ivan Diamond
Robert Jiang
Maria Pia Arolfo
Xiaofen Li
Lina Yao
Zhan Jiang
Wing Ming Keung
Guoxin Tao
Original Assignee
Endowment For Res In Human Biology Inc
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endowment For Res In Human Biology Inc, Gilead Palo Alto Inc filed Critical Endowment For Res In Human Biology Inc
Publication of MA32095B1 publication Critical patent/MA32095B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne de nouveaux dérivés d'isoflavone, dont la structure est représentée par la formule (i), qui se révèlent utiles en tant qu'inhibiteurs d'aldh-2 pour traiter des mammifères qui dépendent de substances créant un effet d'accoutumance, par exemple l'accoutumance à un agent produisant de la dopamine tel que la cocaïne, la morphine, les amphétamines, la nicotine et l'alcool.The present invention relates to novel isoflavone derivatives, whose structure is represented by formula (i), which are useful as inhibitors of aldh-2 for treating mammals that depend on addiction, for example, habituation to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine and alcohol.

MA33106A 2008-01-24 2010-08-23 Inhibitors of aldh-2 in the treatment of addiction MA32095B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
MA32095B1 true MA32095B1 (en) 2011-02-01

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33106A MA32095B1 (en) 2008-01-24 2010-08-23 Inhibitors of aldh-2 in the treatment of addiction

Country Status (13)

Country Link
EP (1) EP2254878A1 (en)
JP (1) JP2011510072A (en)
KR (1) KR20100130589A (en)
CN (1) CN101925590A (en)
AU (1) AU2008348372A1 (en)
BR (1) BRPI0822129A2 (en)
CA (1) CA2712750A1 (en)
EC (1) ECSP10010417A (en)
IL (1) IL207127A0 (en)
MA (1) MA32095B1 (en)
MX (1) MX2010008111A (en)
WO (1) WO2009094028A1 (en)
ZA (1) ZA201004671B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (en) * 2011-02-18 2011-08-24 中国药科大学 Preparation method and applications of isoflavone type compounds with selective estrogen receptor modulating activity
TWI567061B (en) 2011-07-01 2017-01-21 吉李德科學股份有限公司 Compounds for the treatment of addiction
AR087700A1 (en) * 2011-08-30 2014-04-09 Gilead Sciences Inc ALDH-2 INHIBITORS IN ADDICTION TREATMENT
WO2019079209A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. Combination therapy for preventing addiction
CN108276374B (en) * 2018-03-29 2020-01-31 天津科技大学 Flavonoid aromatase inhibitor and preparation method and application thereof
CN110922394B (en) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 Bio-based intrinsic flame-retardant epoxy resin precursor based on natural flavonoid compound and preparation method and application thereof
WO2023235753A2 (en) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
WO2023244584A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (en) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP1077697B1 (en) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
JP4933730B2 (en) * 2001-05-04 2012-05-16 パラテック ファーマシューティカルズ インコーポレイテッド Transcription factor modulating compounds and methods of use thereof
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
EP1542675A4 (en) * 2002-06-27 2008-11-19 Endowment For Res In Human Bio Compounds useful for the inhibition of aldh
JP2008504292A (en) * 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
PL377180A1 (en) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Application of isoflavones and their derivatives in Mucopolysacharidose treatment
MX2008015765A (en) * 2006-07-27 2009-03-26 Cv Therapeutics Inc Aldh-2 inhibitors in the treatment of addiction.
KR20100097675A (en) * 2007-11-06 2010-09-03 씨브이 쎄러퓨틱스, 인코포레이티드 Aldh-2 inhibitors in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
CA2712750A1 (en) 2009-07-30
JP2011510072A (en) 2011-03-31
ZA201004671B (en) 2011-03-30
AU2008348372A1 (en) 2009-07-30
KR20100130589A (en) 2010-12-13
IL207127A0 (en) 2010-12-30
CN101925590A (en) 2010-12-22
WO2009094028A1 (en) 2009-07-30
BRPI0822129A2 (en) 2015-06-23
MX2010008111A (en) 2010-11-30
ECSP10010417A (en) 2010-11-30
EP2254878A1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
MA32095B1 (en) Inhibitors of aldh-2 in the treatment of addiction
MA30434B1 (en) ALDH-2 INHIBITORS FOR TREATMENT OF ACCUSSION
MA35404B1 (en) Compounds for the treatment of drug addiction
MA32684B1 (en) Picolinamide derivatives act as kinase inhibitors
MA30228B1 (en) Monomocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines
MA28077A1 (en) 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TNSN07305A1 (en) PYY AGONISTS AND USES THEREOF
MA31574B1 (en) PYRAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF RAF
MA31084B1 (en) GPCR AGONIST PIPERIDINE DERIVATIVES
MA33836B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LIGANDS OF SIGMA RECEPTORS
MA30351B1 (en) TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE
MA33737B1 (en) Antraquinone derivatives and their use
MA29915B1 (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
MA33072B1 (en) PYRIDAZINONE COMPOUNDS
MA32171B1 (en) Heterocyclic formulations
MA32903B1 (en) PROTEIN-KINASE INHIBITORS
MA31710B1 (en) (Carboxylalkylphenyl) Phenloxamide, its production processes and its use as a drug
MA38170B1 (en) New indanyloxydihydrobenzofuranylacetic acids
MA31158B1 (en) Tricyclic compounds and their use as modifiers for glucocorticoid receptors.
MA30333B1 (en) AMINOTETRAHYDROPYRANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
MA30916B1 (en) NOVEL BENZAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS
TN2014000420A1 (en) INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK
MA30762B1 (en) SPECIFIC ANTIBODIES OF PRLR AND USES THEREOF
MA30607B1 (en) SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES INSTEAD OF P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE
TN2009000138A1 (en) Biaryl-ETHER-UREA